Merck & Co., Inc.
Could not find a ticker for this position, may be a filing error
A maker of prescription medicines and animal health products, Merck produces well-known drugs like the cancer treatment Keytruda and the HPV vaccine Gardasil, along with livestock and pet-care vaccines used by doctors, veterinarians, and farmers. Founded in 1891 as the American branch of a German family firm, the company was seized during World War I and later bought back, becoming an independent U.S. company that today goes by the name MSD outside North America. A fun quirk: its blockbuster Keytruda nearly got shelved — researchers originally set out to calm the immune system, not fight cancer.
Granted 6.49M · Bought 32.0K · Sold 5.49M
Granted 1.75M · Sold 1.25M
Granted 275.0K
Granted 805.9K · Sold 651.4K
Granted 631.0K · Sold 456.3K
Granted 430.7K · Sold 225.4K
Granted 1.08M · Sold 992.0K
Granted 907.8K · Sold 719.6K
Granted 643.3K · Sold 420.0K
Granted 100.0K · Sold 100.0K
Granted 92.2K
Granted 247.4K · Sold 138.2K
Granted 204.6K · Bought 15.8K
Granted 142.1K · Sold 103.0K
Granted 619.8K · Sold 449.8K
Granted 150.7K · Sold 40.0K
Granted 94.6K · Sold 40.0K
Granted 195.0K
Granted 128.5K · Sold 40.0K
Granted 175.6K · Sold 98.6K
Granted 305.1K · Sold 387.8K
Granted 3.0K
Granted 240.0K · Sold 209.3K
Granted 213.8K · Sold 184.1K
Granted 503.9K · Sold 430.9K
Granted 379.6K · Sold 300.1K
Granted 135.0K · Sold 35.5K
Granted 271.5K · Sold 137.0K
Granted 14.7K
Granted 432.9K · Sold 404.7K
Granted 97.2K · Sold 80.7K
Granted 552
Granted 197.3K · Sold 145.5K
Granted 59.8K · Sold 47.0K
Granted 50.4K
Granted 157.5K · Sold 103.8K
Granted 23.3K
Granted 68.1K · Sold 28.6K
Granted 12.3K · Bought 409 · Sold 6.1K
Granted 10.9K
Granted 22.2K · Sold 5.0K
Granted 11.5K
Granted 138.4K · Sold 107.2K
Granted 20.7K
Granted 114.0K · Sold 95.5K
Granted 12.6K
Granted 62.4K · Sold 40.5K
Granted 16.4K
Bought 15.0K
Granted 24.8K
Granted 5.0K · Sold 5.0K
Granted 34.0K · Sold 30.0K
Granted 11.4K
Granted 10.1K
Granted 14.8K · Sold 10.7K
Granted 8.3K
Granted 35.2K · Sold 35.1K
Granted 20.1K · Sold 15.0K
Granted 4.3K
Granted 5.8K
Granted 3.8K
Granted 11.6K
Bought 2.8K
Granted 2.5K
Granted 10.1K · Sold 8.1K
Granted 1.1K
Granted 37.5K · Sold 35.0K
Granted 1.0K
Granted 1.0K
Granted 5.6K · Sold 5.5K
Granted 20
Granted 1.12M · Sold 900.0K
Granted 9.4K · Sold 9.4K
Granted 11.2K · Bought 8.0K
Granted 600.0K · Bought 110.0K
Granted 16.5K
Granted 71.0K
Granted 10.9K
Granted 135.0K
Bought 10.0K
Granted 14.2K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Frazier Kenneth CExecutive Chair, Director · 144 transactions | — | 1.65Mas of Nov 2022 | 6.49M | 32.0K | 5.49M |
| Davis Robert MChairman, CEO & President, Director · 35 transactions | — | 450.4K | 1.75M | — | 1.25M |
| Clark Richard TChairman, Director · 6 transactions | — | 429.7Kas of Mar 2011 | 275.0K | — | — |
| DeLuca Richard R.EVP&Pres, Merck Animal Heallth · 44 transactions | — | 325.7K | 805.9K | — | 651.4K |
| Chattopadhyay SanatExe V-P & Pres. MMD · 43 transactions | — | 258.3K | 631.0K | — | 456.3K |
| Perlmutter Roger MExe V-P & Pres, MRL · 9 transactions | — | 215.1Kas of May 2020 | 430.7K | — | 225.4K |
| Schechter Adam HEVP & Pres-Global Human Health · 59 transactions | — | 210.8Kas of Nov 2018 | 1.08M | — | 992.0K |
| Kuhlik Bruce NExe V-P & Gen Counsel · 49 transactions | — | 206.5Kas of May 2015 | 907.8K | — | 719.6K |
| Kim Peter SExe V-P & Pres, MRL · 17 transactions | — | 191.0Kas of Feb 2013 | 643.3K | — | 420.0K |
| Pickett Cecil BVice President · 2 transactions | — | 168.5Kas of Aug 2006 | 100.0K | — | 100.0K |
| Scalet J ChrisExe V-P Global Srvs & CIO · 13 transactions | — | 165.5Kas of May 2012 | 92.2K | — | — |
| Kohan Raul EExe Vice President · 50 transactions | — | 158.3Kas of Jan 2012 | 247.4K | — | 138.2K |
| Kellogg Peter NExe V-P & CFO · 19 transactions | — | 149.6Kas of Feb 2014 | 204.6K | 15.8K | — |
| Clyburn FrankEVP & Pres ? Human Health · 28 transactions | — | 138.6Kas of Nov 2021 | 142.1K | — | 103.0K |
| Deese Willie AExe V-P & Pres. MMD · 70 transactions | — | 134.5Kas of Feb 2016 | 619.8K | — | 449.8K |
| Guindo ChirfiEVP, Access, Policy & Comms · 13 transactions | — | 124.3K | 150.7K | — | 40.0K |
| Barshay Stanley FExVP&PresConsHlthCare · 16 transactions | — | 112.3Kas of Mar 2010 | 94.6K | — | 40.0K |
| Bertolini Robert JExecutive Vice President · 10 transactions | — | 110.7Kas of Nov 2009 | 195.0K | — | — |
| Li Dean YExecutive VP & President, MRL · 25 transactions | — | 94.4K | 128.5K | — | 40.0K |
| Litchfield CarolineEVP & CFO · 25 transactions | — | 92.3K | 175.6K | — | 98.6K |
| Graddick Weir Mirian MExe V-P, HR · 37 transactions | — | 80.4Kas of May 2018 | 305.1K | — | 387.8K |
| Osborne Richard De JDirector · 1 transaction | — | 78.3Kas of May 2006 | 3.0K | — | — |
| Bowles Richard S IIIExe VP&Chief Ethics & ComplOff · 37 transactions | — | 77.5Kas of May 2012 | 240.0K | — | 209.3K |
| Mizell StevenEVP, Chief HR Officer · 33 transactions | — | 74.3Kas of Feb 2024 | 213.8K | — | 184.1K |
| Zachary JenniferEVP, General Counsel · 30 transactions | — | 70.9K | 503.9K | — | 430.9K |
| Holston Michael JEVP, General Counsel · 16 transactions | — | 69.8Kas of Feb 2018 | 379.6K | — | 300.1K |
| Saunders Brent LSenior Vice President · 17 transactions | — | 50.8Kas of Nov 2009 | 135.0K | — | 35.5K |
| Cheeley C RonSenior Vice President · 28 transactions | — | 50.1Kas of Nov 2009 | 271.5K | — | 137.0K |
| Klobuchar Michael AEVP - Chief Strategy Officer · 15 transactions | — | 49.5Kas of May 2024 | 14.7K | — | — |
| Gerberding Julie L.EVP, Chief Patient Officer · 35 transactions | — | 48.7Kas of Feb 2022 | 432.9K | — | 404.7K |
| Golestani ClarkEVP & Chief Info Officer · 27 transactions | — | 47.6Kas of Aug 2016 | 97.2K | — | 80.7K |
| Maraldo David R.EVP & Pres. MMD · 2 transactions | — | 44.9K | 552 | — | — |
| Karachun Rita ASr. VP Fince-Global Controller · 57 transactions | — | 44.6Kas of May 2023 | 197.3K | — | 145.5K |
| Watson AshleySVP Chief Ethics & Com Officer · 7 transactions | — | 43.0Kas of Nov 2018 | 59.8K | — | 47.0K |
| Rosenblatt MichaelExec V-P & Chief Med Officer · 12 transactions | — | 41.5Kas of May 2016 | 50.4K | — | — |
| Heller Bridgette PExe.VP & Pres.Con.Hlth.Care · 11 transactions | — | 35.5Kas of May 2014 | 157.5K | — | 103.8K |
| Nally MichaelEVP, Chief Marketing Officer · 15 transactions | — | 32.1Kas of Mar 2021 | 23.3K | — | — |
| Williams David MichaelEVP,Chief Info&Digital Officer · 35 transactions | — | 31.7K | 68.1K | — | 28.6K |
| Romanelli JosephPresident, Human Health Int?l · 20 transactions | — | 28.7K | 12.3K | 409 | 6.1K |
| Turner MervynChief Strategy Officer · 7 transactions | — | 28.0Kas of Mar 2011 | 10.9K | — | — |
| Kidder C RobertDirector · 12 transactions | — | 25.7Kas of May 2017 | 22.2K | — | 5.0K |
| Represas Carlos EDirector · 6 transactions | — | 23.0Kas of May 2017 | 11.5K | — | — |
| Ambrose Adele DSr.V-P & Chief Comuns Officer · 32 transactions | — | 22.7Kas of May 2017 | 138.4K | — | 107.2K |
| Mundy Carl E JrDirector · 8 transactions | — | 21.9Kas of Jun 2009 | 20.7K | — | — |
| Oosthuizen Johannes JacobusEVP, Oncology & Int?l · 38 transactions | — | 21.9K | 114.0K | — | 95.5K |
| Leder PhilipDirector · 7 transactions | — | 19.8Kas of Dec 2008 | 12.6K | — | — |
| Canan JohnSr.V-P Finc-Global Controller · 20 transactions | — | 17.0Kas of Feb 2014 | 62.4K | — | 40.5K |
| Harrison William B JrDirector · 4 transactions | — | 16.4Kas of Apr 2016 | 16.4K | — | — |
| Baker Douglas M JrDirector · 1 transaction | — | 16.0K | — | 15.0K | — |
| Larson Betty DEVP, Chief HR Officer · 6 transactions | — | 13.8K | 24.8K | — | — |
| Russo Patricia FDirector · 3 transactions | — | 13.1K | 5.0K | — | 5.0K |
| Lazarus Rochelle BDirector · 14 transactions | — | 12.7Kas of Apr 2020 | 34.0K | — | 30.0K |
| Scholefield James HEVP,Chief Info&Digital Officer · 2 transactions | — | 11.4Kas of Oct 2019 | 11.4K | — | — |
| Fleming MichaelSVP Chief Ethics & Com Officer · 10 transactions | — | 10.3Kas of Feb 2021 | 10.1K | — | — |
| Becherer Hans WDirector · 1 transaction | — | 9.6Kas of Nov 2006 | — | — | — |
| Smart Dalton E. IIISVP Fin. - Global Controller · 20 transactions | — | 9.4K | 14.8K | — | 10.7K |
| Smart DaltonSVP Fin. - Global Controller · 10 transactions | — | 7.0Kas of Jan 2025 | 8.3K | — | — |
| Weeks Wendell PDirector · 18 transactions | — | 5.1Kas of May 2020 | 35.2K | — | 35.1K |
| Glocer Thomas HDirector · 6 transactions | — | 5.1K | 20.1K | — | 15.0K |
| Kelley Willam NDirector · 2 transactions | — | 4.3Kas of Apr 2012 | 4.3K | — | — |
| LeCointe-Cephas LisaSVP Chief Ethics & Com Officer · 18 transactions | — | 4.2Kas of May 2023 | 5.8K | — | — |
| Jacobson Harry RDirector · 4 transactions | — | 4.0Kas of May 2011 | 3.8K | — | — |
| Thompson Craig B.Director · 4 transactions | — | 3.4Kas of May 2018 | 11.6K | — | — |
| Thulin Inge GDirector · 1 transaction | — | 2.9K | — | 2.8K | — |
| Garay ArpaSVP Human Health Global Mktg. · 6 transactions | — | 2.4Kas of May 2022 | 2.5K | — | — |
| Brun Leslie ADirector · 5 transactions | — | 1.9Kas of Jun 2021 | 10.1K | — | 8.1K |
| Tatlock Anne MDirector · 2 transactions | — | 1.1Kas of Apr 2012 | 1.1K | — | — |
| Wendell Peter CDirector · 14 transactions | — | 1.0Kas of Mar 2024 | 37.5K | — | 35.0K |
| Goldstone Steven FDirector · 1 transaction | — | 1.0Kas of Apr 2012 | 1.0K | — | — |
| Shenk Thomas EDirector · 1 transaction | — | 1.0Kas of May 2011 | 1.0K | — | — |
| Cech Thomas RDirector · 4 transactions | — | 100as of Jun 2020 | 5.6K | — | 5.5K |
| Thier Samuel O MDDirector · 1 transaction | — | 20as of Nov 2009 | 20 | — | — |
| Cox Carrie SmithExecutive Vice President · 38 transactions | — | 0as of Nov 2009 | 1.12M | — | 900.0K |
| Downing Cristal NChief Comm. & Public Afrs Ofcr · 3 transactions | — | 0 | 9.4K | — | 9.4K |
| Colligan Thomas JDirector · 10 transactions | — | 0as of Nov 2009 | 11.2K | 8.0K | — |
| Hassan FredChairman and CEO, Director · 16 transactions | — | 0as of Nov 2009 | 600.0K | 110.0K | — |
| Koehler Steven HVice President and Controller · 5 transactions | — | 0as of Nov 2009 | 16.5K | — | — |
| Koestler Thomas PExecutive Vice President · 9 transactions | — | 0as of Nov 2009 | 71.0K | — | — |
| McGrath Eugene RDirector · 7 transactions | — | 0as of Nov 2009 | 10.9K | — | — |
| Sabatino Thomas J JrExecutive Vice President · 7 transactions | — | 0as of Nov 2009 | 135.0K | — | — |
| Stahl Jack LDirector · 3 transactions | — | 0as of Nov 2009 | — | 10.0K | — |
| Turner Kathryn CDirector · 1 transaction | — | 0as of Nov 2009 | — | — | — |
| Van Oordt Robert FWDirector · 9 transactions | — | 0as of Nov 2009 | 14.2K | — | — |
| Weinbach Arthur FDirector · 1 transaction | — | 0as of Nov 2009 | — | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -14.82M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.